Alpa Laboratories Limited (ALPA.BO)
INR 105.3
(1.4%)
INR 105.3
(1.4%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 86.12 Million INR | -44.54% |
| 2022 | 174.43 Million INR | 12.19% |
| 2021 | 106.62 Million INR | 15.81% |
| 2020 | 130.29 Million INR | 9.38% |
| 2019 | 61.67 Million INR | 41.42% |
| 2018 | 64.84 Million INR | -23.81% |
| 2017 | 88.4 Million INR | -24.5% |
| 2016 | 101.3 Million INR | -10.73% |
| 2015 | 68.37 Million INR | 107.87% |
| 2014 | 50.56 Million INR | 9.88% |
| 2013 | 62.3 Million INR | 97.35% |
| 2012 | 31.41 Million INR | 22.24% |
| 2011 | 25.7 Million INR | 138.87% |
| 2010 | 10.75 Million INR | -64.42% |
| 2009 | 32.1 Million INR | 18.75% |
| 2008 | 25.46 Million INR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 5.3 Million INR | -24.02% |
| 2023 Q4 | 35.07 Million INR | -41.2% |
| 2023 Q1 | 32.97 Million INR | -41.68% |
| 2023 Q2 | 63.06 Million INR | 91.26% |
| 2023 Q3 | 59.64 Million INR | -5.41% |
| 2023 FY | - INR | -44.54% |
| 2022 Q2 | 6.39 Million INR | -79.2% |
| 2022 FY | - INR | 12.19% |
| 2022 Q4 | 56.53 Million INR | 6.78% |
| 2022 Q3 | 52.95 Million INR | 728.12% |
| 2022 Q1 | 30.73 Million INR | 28.26% |
| 2021 Q3 | 59.25 Million INR | -4.39% |
| 2021 Q4 | 23.96 Million INR | -59.56% |
| 2021 Q2 | 61.97 Million INR | -8.92% |
| 2021 Q1 | 68.04 Million INR | 272.54% |
| 2021 FY | - INR | 15.81% |
| 2020 Q2 | 12.09 Million INR | -65.59% |
| 2020 Q4 | 18.26 Million INR | -54.95% |
| 2020 Q1 | 35.15 Million INR | 801.2% |
| 2020 FY | - INR | 9.38% |
| 2020 Q3 | 40.54 Million INR | 235.18% |
| 2019 Q3 | 34 Million INR | 181.1% |
| 2019 FY | - INR | 41.42% |
| 2019 Q1 | 20.58 Million INR | 353.71% |
| 2019 Q2 | 12.09 Million INR | -41.24% |
| 2019 Q4 | -5.01 Million INR | -114.74% |
| 2018 Q3 | 33.35 Million INR | 176.91% |
| 2018 Q1 | 1.13 Million INR | 0.0% |
| 2018 FY | - INR | -23.81% |
| 2018 Q4 | -8.11 Million INR | -124.32% |
| 2018 Q2 | 12.04 Million INR | 965.87% |
| 2017 FY | - INR | -24.5% |
| 2016 FY | - INR | -10.73% |
| 2015 FY | - INR | 107.87% |
| 2015 Q2 | 63.68 Million INR | 91.69% |
| 2015 Q1 | 33.22 Million INR | 237421.43% |
| 2014 Q1 | 3.99 Million INR | -65.86% |
| 2014 Q2 | 13.21 Million INR | 230.55% |
| 2014 Q3 | 31.35 Million INR | 137.34% |
| 2014 Q4 | -14 Thousand INR | -100.04% |
| 2014 FY | - INR | 9.88% |
| 2013 FY | - INR | 97.35% |
| 2013 Q2 | 1.29 Million INR | -91.09% |
| 2013 Q3 | 29.19 Million INR | 2149.31% |
| 2013 Q4 | 11.7 Million INR | -59.91% |
| 2013 Q1 | 14.56 Million INR | 45.7% |
| 2012 Q3 | 8.09 Million INR | 136.15% |
| 2012 Q2 | 3.42 Million INR | -67.51% |
| 2012 Q1 | 10.54 Million INR | 392.55% |
| 2012 FY | - INR | 22.24% |
| 2012 Q4 | 9.99 Million INR | 23.53% |
| 2011 Q3 | 9.09 Million INR | 0.0% |
| 2011 Q4 | 2.14 Million INR | -76.45% |
| 2011 FY | - INR | 138.87% |
| 2010 FY | - INR | -64.42% |
| 2009 FY | - INR | 18.75% |
| 2008 FY | - INR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 9.61 Billion INR | 99.104% |
| Aurobindo Pharma Limited | 61.78 Billion INR | 99.861% |
| Glenmark Life Sciences Limited | 6.86 Billion INR | 98.745% |
| Granules India Limited | 8.6 Billion INR | 98.999% |
| Indoco Remedies Limited | 2.64 Billion INR | 96.746% |
| Achyut Healthcare Limited | 524 Thousand INR | -16336.45% |
| Ajanta Pharma Limited | 12.56 Billion INR | 99.315% |
| Alkem Laboratories Limited | 24.19 Billion INR | 99.644% |
| Brooks Laboratories Limited | 41.72 Million INR | -106.401% |
| AstraZeneca Pharma India Limited | 2.35 Billion INR | 96.346% |
| Bajaj HealthCare Limited | 444.51 Million INR | 80.625% |
| Bliss GVS Pharma Limited | 1.47 Billion INR | 94.177% |
| Dr. Reddy's Laboratories Limited | 88.27 Billion INR | 99.902% |
| Eris Lifesciences Limited | 6.98 Billion INR | 98.767% |
| FDC Limited | 4.4 Billion INR | 98.043% |
| Glenmark Pharmaceuticals Limited | 11.34 Billion INR | 99.241% |
| Gufic Biosciences Limited | 1.48 Billion INR | 94.183% |
| Ind-Swift Laboratories Limited | 6.86 Billion INR | 98.745% |
| Ipca Laboratories Limited | 13.29 Billion INR | 99.352% |
| Jagsonpal Pharmaceuticals Limited | 323.46 Million INR | 73.373% |
| Krebs Biochemicals & Industries Limited | -82.72 Million INR | 204.11% |
| Lasa Supergenerics Limited | -65.08 Million INR | 232.34% |
| Laurus Labs Limited | 8 Billion INR | 98.924% |
| Lupin Limited | 36.96 Billion INR | 99.767% |
| Mankind Pharma Limited | 28.09 Billion INR | 99.693% |
| Medicamen Biotech Limited | 245.66 Million INR | 64.941% |
| Medico Remedies Limited | 150.37 Million INR | 42.726% |
| Megasoft Limited | 284.73 Million INR | 69.751% |
| NATCO Pharma Limited | 18.79 Billion INR | 99.542% |
| Piramal Pharma Limited | 13.05 Billion INR | 99.34% |
| RPG Life Sciences Limited | 1.28 Billion INR | 93.279% |
| Sigachi Industries Limited | 883.39 Million INR | 90.25% |
| Sun Pharmaceutical Industries Limited | 138.36 Billion INR | 99.938% |
| Suven Pharmaceuticals Limited | 4.67 Billion INR | 98.159% |
| Syncom Formulations (India) Limited | 430.27 Million INR | 79.983% |
| Unichem Laboratories Limited | 742.35 Million INR | 88.398% |
| Wanbury Limited | 985.49 Million INR | 91.26% |
| Windlas Biotech Limited | 781.72 Million INR | 88.982% |
| ZIM Laboratories Limited | 462.09 Million INR | 81.362% |
| Zydus Lifesciences Limited | 56.22 Billion INR | 99.847% |
| Sun Pharma Advanced Research Company Limited | -3.73 Billion INR | 102.308% |
| Divi's Laboratories Limited | 25.43 Billion INR | 99.661% |
| Hester Biosciences Limited | 539.47 Million INR | 84.035% |
| Procter & Gamble Health Limited | 3.01 Billion INR | 97.143% |
| Amrutanjan Health Care Limited | 682.53 Million INR | 87.381% |
| Bal Pharma Limited | 345.59 Million INR | 75.078% |
| Strides Pharma Science Limited | 3.76 Billion INR | 97.712% |
| Venus Remedies Limited | 711.8 Million INR | 87.9% |
| Aarti Pharmalabs Limited | 3.9 Billion INR | 97.797% |
| Nectar Lifesciences Limited | 1.56 Billion INR | 94.492% |
| Shilpa Medicare Limited | 2.58 Billion INR | 96.672% |
| Aarti Drugs Limited | 3.24 Billion INR | 97.349% |
| IOL Chemicals and Pharmaceuticals Limited | 2.6 Billion INR | 96.696% |
| Suven Life Sciences Limited | -992.78 Million INR | 108.675% |
| Ind-Swift Limited | 1.06 Billion INR | 91.913% |
| Valiant Laboratories Limited | 12.73 Million INR | -576.089% |
| J. B. Chemicals & Pharmaceuticals Limited | 9.33 Billion INR | 99.077% |
| Solara Active Pharma Sciences Limited | -2.82 Billion INR | 103.052% |
| Themis Medicare Limited | 562.6 Million INR | 84.691% |
| Hikal Limited | 2.69 Billion INR | 96.801% |
| Torrent Pharmaceuticals Limited | 35 Billion INR | 99.754% |
| Sequent Scientific Limited | 549.8 Million INR | 84.335% |
| Novartis India Limited | 1.26 Billion INR | 93.215% |
| Wockhardt Limited | 1.08 Billion INR | 92.025% |
| Jubilant Pharmova Limited | 8 Billion INR | 98.924% |
| Biofil Chemicals and Pharmaceuticals Limited | 13.06 Million INR | -559.371% |
| Neuland Laboratories Limited | 4.74 Billion INR | 98.186% |
| Morepen Laboratories Limited | 1.72 Billion INR | 95.01% |
| Kilitch Drugs (India) Limited | 287.42 Million INR | 70.035% |
| Mangalam Drugs & Organics Limited | 174.94 Million INR | 50.769% |